Shanghai Haohai Biological Technology Co. Ltd Market Cap ($73.19 Million)
Market Cap & Net Worth: Shanghai Haohai Biological Technology Co. Ltd (5HB)
Shanghai Haohai Biological Technology Co. Ltd market cap. Shanghai Haohai Biological Technology Co. Ltd (F:5HB) has a market capitalization of $73.19 Million (€62.60 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #20262 globally and #1842 in its home market, demonstrating a 3.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Haohai Biological Technology Co. Ltd's stock price €1.80 by its total outstanding shares 34780340 (34.78 Million). Also see 5HB cash flow conversion for how efficiently the company converts equity into cash flow.
Shanghai Haohai Biological Technology Co. Ltd Market Cap History (2015–2026)
Shanghai Haohai Biological Technology Co. Ltd market cap history from 2015 to 2026. Data shows growth from $32.79 Million to $73.19 Million (8.68% CAGR). Check Shanghai Haohai Biological Technology Co stock quote for real-time trading data and today's change.
Shanghai Haohai Biological Technology Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Haohai Biological Technology Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Shanghai Haohai Biological Technology Co to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.04x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.42x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $29.34 Million | $851.16 Million | $305.05 Million | 0.03x | 0.10x |
| 2017 | $29.61 Million | $1.34 Billion | $372.42 Million | 0.02x | 0.08x |
| 2018 | $34.82 Million | $1.55 Billion | $414.54 Million | 0.02x | 0.08x |
| 2019 | $47.56 Million | $1.60 Billion | $370.78 Million | 0.03x | 0.13x |
| 2020 | $54.45 Million | $1.32 Billion | $230.07 Million | 0.04x | 0.24x |
| 2021 | $67.37 Million | $1.75 Billion | $352.23 Million | 0.04x | 0.19x |
| 2022 | $65.69 Million | $2.10 Billion | $180.47 Million | 0.03x | 0.36x |
| 2023 | $78.13 Million | $2.63 Billion | $416.12 Million | 0.03x | 0.19x |
| 2024 | $131.74 Million | $2.68 Billion | $420.45 Million | 0.05x | 0.31x |
| 2025 | $106.53 Million | $2.45 Billion | $251.01 Million | 0.04x | 0.42x |
Competitor Companies of 5HB by Market Capitalization
Companies near Shanghai Haohai Biological Technology Co. Ltd in the global market cap rankings as of November 4, 2026. Also see 5HB current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Shanghai Haohai Biological Technology Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Shanghai Haohai Biological Technology Co. Ltd (2015–2026)
Market capitalization of Shanghai Haohai Biological Technology Co. Ltd from 2015 to today. Between 2015 and today, Shanghai Haohai Biological Technology Co. Ltd's market cap moved from $32.79 Million to $ 73.19 Million, with a yearly change of 8.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €73.19 Million | -31.30% |
| 2025 | €106.53 Million | -19.14% |
| 2024 | €131.74 Million | +68.63% |
| 2023 | €78.13 Million | +18.94% |
| 2022 | €65.69 Million | -2.49% |
| 2021 | €67.37 Million | +23.72% |
| 2020 | €54.45 Million | +14.49% |
| 2019 | €47.56 Million | +36.58% |
| 2018 | €34.82 Million | +17.59% |
| 2017 | €29.61 Million | +0.93% |
| 2016 | €29.34 Million | -10.53% |
| 2015 | €32.79 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Shanghai Haohai Biological Technology Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $73.19 Million USD |
| MoneyControl | $73.19 Million USD |
| MarketWatch | $73.19 Million USD |
| marketcap.company | $73.19 Million USD |
| Reuters | $73.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more